Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins

Abstract Purpose The objective of this study is to determine primary survival endpoints in women with recurrent and metastatic endometrial carcinoma (RMEC) treated with progestins. Methods A retrospective chart review was conducted at The Ottawa Hospital using electronic medical records. Inclusion c...

Full description

Bibliographic Details
Main Authors: A. Kulkarni, N. M. Andrews Wright, A. N. Forget, T. Ramsay, R. Mallick, J. I. Weberpals
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:Cancer Medicine
Subjects:
death
metastasis
recurrence
skin neoplasms
Online Access:https://doi.org/10.1002/cam4.6276

Similar Items

Similar Items